lobbying_activities: 2461235

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
2461235	5f6ebe1e-a315-4a01-b77a-270334b2a0b1	Q2	JAMES EDWARDS	401027897	CONSERVATIVES FOR PROPERTY RIGHTS	2020	second_quarter	MMM	Proposed International Pricing Index (IPI) payment model for drugs administered under Medicare Part B S. 377/H.R. 1046 (Medicare Negotiation and Competitive Licensing Act) Reform of drug manufacturer rebates to third parties (e.g., pharmaceutical benefits managers, insurers) Proposed binding arbitration for enacting government price controls under Medicare Part D Inflationary penalty as government price controls in Medicare Part D/S. 2543 (Prescription Drug Pricing Reduction Act) S. 1129/H.R. 1384 (Medicare for All Act) Single-payer health care Government price controls on health care products, services, providers, payers H.R. 3 (Elijah E. Cummings Lower Drug Costs Now Act) drug price controls through international reference pricing, direct federal price dictation, confiscatory penalty on the most innovative medicines Importation of Prescription Drugs Proposed Rule (Docket No. FDA-2019-N-5711) H.R. 1425 (Patient Protection and Affordable Care Enhancement Act) H.R. 6674 (Medicare Crisis Program Act)	Council on Environmental Quality (CEQ),Environmental Protection Agency (EPA),Executive Office of the President (EOP),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),Patent & Trademark Office (PTO),SENATE	10000		0	0	2020-07-06T09:07:03.570000-04:00